$GTCH "We are expanding our qTerm’s testing scale as

New Post Public Reply Private Reply Replies (0) Message Board
Lets Roll
135
$GTCH "We are expanding our qTerm’s testing scale as phase I testing produced very successful results. qTerm GEN II has proven to offer better compatibility for the general population with accurate result’s and overall reliability. Phase II testing will include a larger number of users within wider age group, diverse health conditions, lifestyle and occupation. We are interested to learn more about how, where and when people will be using the device, throughout their daily lives. We will evaluate qTerm prototype for user’s measurement habits and record the data for further analysis. GEN II version improvements significantly increase the device’s overall performance, accuracy and consistency. We target the larger scale testing to be used as part of the potential FDA certification process. qTerm’s device is planned for personal and telemedicine usages. Based on the larger scale data we expect to fine tune the device’s software and mobile application. The device is planned to include an Artificial Intelligence technology that will be offering personal calibration, real-time health statistics and monitoring. One of the major aspects for our larger testing group is to get more data about the devices ease of use and user friendliness aspects. The larger scale testing is planned to take about 30 days, which shortly after, we plan to start creating a commercial version to be handed in. We have a wide variety of potential business partners and customers for qTerm and believe that it can be an efficient health monitoring device. As part of our thorough quality assurance processes we are on a constant mission to ensure the device’s highest performance, bringing it to the highest standards and industry’s regulations" Said Danny Rittman the Company’s CTO

https://seekingalpha.com/pr/18395159-gbt-laun...-prototype
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

BIC's Latest Voting Rights and Shares Disclosure Details

Updated Category News Views 180

Key Disclosure on Voting Rights and Shares As a reputable leader in stationery and consumer products, BIC is committed to transparency. Recently, they provided crucial insights into their corporate structure, particularly regarding the total number of voting rights and shares. This disclosure highlights the ongoing dedication towards maintaining clear communication with...

Continue Reading
AGCO Showcase: Innovations and Autonomy for 2026 Farmers

Updated Category News Views 212

AGCO (NYSE: AGCO) is strutting its stuff at the 2026 Commodity Classic in San Antonio from February 25-27. Picture this: over 24,000 square feet jam-packed with cutting-edge agricultural machinery aimed at farmers who want to boost their operations. Yeah, the buzz is all about showcasing their big guns like Fendt®, Massey Ferguson®, and PTx™—but dig deeper into...

Continue Reading
Revolutionizing Healthcare Marketing with Ignite Pulse Solutions

Updated Category News Views 371

Revolutionizing Healthcare Marketing with Ignite Pulse Solutions In the shifting landscape of healthcare marketing, WebMD Ignite introduces a significant enhancement aimed at assisting health systems in thriving amidst the challenges posed by AI and budget constraints. Presenting Ignite Pulse™, this groundbreaking solution offers a comprehensive growth strategy designed...

Continue Reading
Eupraxia Pharmaceuticals Welcomes New Leaders to Innovate Growth

Updated Category News Views 190

Eupraxia Pharmaceuticals Expands Leadership Team Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX), known for its innovative approaches in drug delivery technology, has recently announced two significant additions to its leadership. Dr. Amanda Malone has been appointed as the Chief Operating and Scientific Officer, alongside Dr. Rahul Sarugaser as Executive Vice...

Continue Reading
Illumina Enhances Oncology Solutions for Better Cancer Care

Updated Category News Views 186

Illumina's Latest Developments in Oncology In an exciting development, Illumina Inc. (NASDAQ: ILMN) has announced a significant expansion in its clinical oncology portfolio. This move aims to set a new standard of care and enhance access to precision therapies through advanced genomic profiling. Following the recent FDA approval of Illumina's TSO Comprehensive test, the...

Continue Reading